Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals announced a $125 million capital infusion through the sale of a Priority Review Voucher and a drawdown from an existing loan facility. This extends their cash runway into late 2025, excluding expected commercial sales from XOLREMDI™, the first drug approved for patients with WHIM syndrome.
X4 Pharmaceuticals reported financial results for the first quarter of 2024, with $81.6 million in cash. The FDA approved XOLREMDI for WHIM syndrome, and a Phase 3 trial data was published. Interim data from a Phase 2 trial in chronic neutropenia is expected in June 2024. X4 plans to initiate a Phase 3 trial for autoimmune and chronic neutropenia. The company expects EMA approval for mavorixafor in late 2024/early 2025.
Despite promising developments, X4 reported an increase in R&D and SG&A expenses, leading to a net loss of $51.8 million for the first quarter of 2024.
X4 Pharmaceuticals announced the issuance of inducement awards to new employees under the 2019 Inducement Plan, consisting of options to purchase 605,349 shares of X4's common stock. The options have a ten-year term, with an exercise price of $1.12 per share, and will vest over a four-year period, subject to continued employment.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.
FAQ
What is the current stock price of X4 Pharmaceuticals (XFOR)?
What is the market cap of X4 Pharmaceuticals (XFOR)?
